Cardiology

Biotech

FDA approves Amarin fish-oil-derived drug to prevent heart attacks and strokes

By Matthew Herper

Biotech

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

By Matthew Herper

Biotech

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

By Chris Morrison

Health

Big study casts doubt on need for many heart procedures

By Associated Press

Health

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers

By Rebecca Robbins

Biotech

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

By Adam Feuerstein and Matthew Herper

Biotech

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

By Matthew Herper and Adam Feuerstein

Health

Cholesterol levels dropping in U.S., but many still need care

By Associated Press

Biotech

Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill

By Adam Feuerstein

Biotech

Cleveland Clinic’s Nissen denies any communication with FDA about Amarin’s Vascepa

By Matthew Herper

Pharma

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

By Damian Garde

Health

An AI startup, led by 23andMe veteran Andy Page, tries to take better pictures of the heart

By Matthew Herper

Pharmalot

Sandoz halts global distribution of heartburn med over carcinogen link while Canada tells other manufacturers to stop

By Ed Silverman

Pharmalot

FDA and EMA are now probing carcinogen in Zantac and other heartburn meds

By Ed Silverman

Health

Some 9/11 firefighters may have higher heart risks now

By Associated Press

Biotech

Regeneron drug proves effective in genetic form of high cholesterol

By Matthew Herper and Damian Garde

Biotech

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

By Adam Feuerstein

Health Tech

5 ways artificial intelligence is already changing cardiac care

By Casey Ross

Health

Study: Millions should stop using aspirin for heart health

By Associated Press

In the Lab

A family’s medical mystery sheds light on the surprising ways disease-causing genes can be inherited

By Andrew Joseph

In the Lab

Attempt to replicate clinical trials with real-world data generates real-world criticism, too

By Matthew Herper

Business

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

By Adam Feuerstein

First Opinion

In a medical emergency, who in your social network will call for help quickest?

By Amar Dhand

In the Lab

‘Alexa, are you listening?’ An experimental tool warns of cardiac arrest by monitoring breathing

By Diana Cai

Health

Patients whose blood pressure only spikes at the doctor’s office are twice as likely to die of a heart attack or other cardiac event

By Ruth Hailu

‘Donation after cardiac death’: New heart transplant method being tested for the first time in the U.S.

Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better?

AstraZeneca fish oil drug fails, leaving Amarin as last drug standing

At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help real patients?

FDA approves Amarin fish-oil-derived drug to prevent heart attacks and strokes

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

Big study casts doubt on need for many heart procedures

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

Cholesterol levels dropping in U.S., but many still need care

Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill

Cleveland Clinic’s Nissen denies any communication with FDA about Amarin’s Vascepa

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

An AI startup, led by 23andMe veteran Andy Page, tries to take better pictures of the heart

Sandoz halts global distribution of heartburn med over carcinogen link while Canada tells other manufacturers to stop

FDA and EMA are now probing carcinogen in Zantac and other heartburn meds

Some 9/11 firefighters may have higher heart risks now

Regeneron drug proves effective in genetic form of high cholesterol

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

5 ways artificial intelligence is already changing cardiac care

Study: Millions should stop using aspirin for heart health

A family’s medical mystery sheds light on the surprising ways disease-causing genes can be inherited

Attempt to replicate clinical trials with real-world data generates real-world criticism, too

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

In a medical emergency, who in your social network will call for help quickest?

‘Alexa, are you listening?’ An experimental tool warns of cardiac arrest by monitoring breathing

Patients whose blood pressure only spikes at the doctor’s office are twice as likely to die of a heart attack or other cardiac event